Imeka

Imeka is currently the only company to combine diffusion imaging and AI to map white matter integrity and get insights on neuroinflammation, demyelination and axonal loss. Therefore, with our non-invasive technology, we minimize risks for our pharma and biotech clients in the development of treatments for neurodegenerative diseases. Imekas main goal is to play an influential role in the search and development of cures for brain disease. Imekas diffusion imaging tools are able to measure extracellular water fraction (free-water), which is sensitive neuroinflammation. The technology pioneered by Imeka enhances white matter imaging and has applications in important brain disease areas...

Diffusion mri service,dti,hardi,brain mri micro-structure,medical imaging,diffusion mri,neurosurgery prep,white matter imaging,free-water imaging,fiber tractography,fiber bundling,tractography,brain imaging,multiple sclerosis,alzheimer,parkinson,neurodegenerative diseases,neuroimaging,and neuroinflammation

Imeka operates in the Biotechnology research industry.

Imeka's revenue is 11m - 100m

Imeka has 11 - 50 employees.